BMS and Celgene Merge as Amgen Buys Otezla

Save

Bristol-Myers Squibb (BMS) has completed its $74 billion acquisition of Celgene. With the acquisition complete, Celgene is now a wholly-owned subsidiary of BMS. The combined companies have nine products with more than $1 billion in annual sales.

Pegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout

Save

Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades.

RheumNow Podcast –Favorites of ACR 2019 (11.22.19)

Save

Dr. Jack Cush recaps standout presentations and information from ACR 2019 held in Atlanta November 9-12, 2019.

ACR 2019 - Report From Day 3 (Tuesday)

Save

Here's my summary of key studies presented Tuesday. 

Tofacitinib in Polyarticular JIA

Psoriatic Arthritis at ACR 2019

Save

Below are several of the highlight studies in psoriatic arthritis (PsA) presented at the ACR 2019 annual meeting in Atlanta. 

ACR 2019 – Best of the Plenary Sessions

Save

The ACR Plenary Sessions featured some of the best research presented on Sunday, Monday, and Tuesday in Atlanta. Here are my seven notable highlights from the Plenaries.

ACR 2019 - Report from Day One (Sunday)

Save

Sunday was the first full day of scientific sessions at the 2019 ACR/ARP meeting in Atlanta. Yesterday we shared our initial news articles, videos and more with you. Following is my roundup of day one. 

Delays in Diagnosis

New Treatments in Axial SpA from #ACR2019

Save

There were new developments in the treatment of axial Spondyloarthritis (AS) at ACR 2019. The first area is on the use of anti-IL17A drugs, secukinumab and ixekizumab in non-radiographic AS. The second area is the use of JAK-1 inhibitor Upadacitinib in radiographic AS.

RheumNow Podcast – ACR 2019 Round Up (11.15.19)

Save

Dr. Jack Cush presents his favorite abstracts and presentations from Rheumatology Round Up and ACR 2019.

RheumNow Podcast – Better Ways to Treat Gout (11.8.19)

Save

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Most Psoriatics Go on Biologics

Save

A cohort study of 97 patients with psoriatic arthritis (PsA) examined the prescribing practices in PsA, and found biologics are commonly initiated as the primary mode of therapy in outpatients with PsA. However, treatment modifications can be made regarding patients who are managed with apremilast alone.

New EMA Warnings for Tofacitinib in Patients at Risk for Clots

Save

The European Medicines Agency safety committee (PRAC) has concluded that Xeljanz (tofacitinib - TOFA) could increase the risk of blood clots in the lungs and in deep veins in patients who are already at high risk for venous thromboembolic events. The PRAC is recommending that TOFA should be used with caution in patients at high risk of blood clots (VTE), regardless of dose used.

RheumNow Podcast – Ghastly, Ghoulish News (10.31.19)

Save

Dr. Jack Cush reviews recent journal articles and info bits from the past week on RheumNow.com. 

Outcomes in Juvenile Idiopathic Arthritis

Save

Arthritis Research & Therapy reports on a prospective cohort of children with juvenile idiopathic arthritis (JIA) shows that the incidence has held steady at 12.8/100,000 children, but that the frequency uveitis and the need for orthopedic surgery has decreased in the last 20 years.

FDA Approves Ustekinumab for Ulcerative Colitis

Save

Ustekinumab (Stelara) is now FDA-approved to treat moderately to severely active ulcerative colitis, said drugmaker Janssen on Monday, in addition to its indications for psoriasis, psoriatic arthritis, and Crohn's disease.

Adalimumab and Pregnancy Outcomes

Save

A prospective study of birth outcomes to mothers exposed to adalimumab (ADA) between 2004 and 2016 was conducted by Organization of Teratology Information Specialists (OTIS) Research Center at the University of California San Diego, and showed that ADA exposure was not associated with an increase

Interleukin Targeted Biologics Increase Risks of Infection

Save

A systematic review of the literature shows that, compared to placebo, the use of non-TNF, interleukin inhibitor biologics may be associated with significantly higher rates of serious infections, opportunistic infections, and cancer.

RheumNow Podcast – Fight or Switching (DMARDs) (10.18.19)

Save

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

ACR 2018 - Day 1 Report

Save

Highlights from Tuesday and Wednesday (days 3 and 4) from the ACR annual meeting include: the important and impactful abstracts covered by the Rheumatology Roundup session; upadacitinib clinical trials; and the baricitinib CV and VTE safety analysis.